ImmuCell Corp.
Mast Out Facility
Project Overview
- Construction of a new pharmaceutical-grade manufacturing facility
- Aggressive schedule requirements ensured the facility was able to begin production on-time
- Extensive use of pre-fabrication for equipment and building systems
ImmuCell, a Maine-based animal health medicine manufacturer, has expanded its Portland headquarters with a new pharmaceutical-grade production facility. The Mast Out Facility manufactures a treatment for a common infection found in cows worldwide and houses space for fermentation, laboratory, processing and warehouse program areas.
The cGMP manufacturing facility was built in two phases. The first phase was the construction of the core and shell and the second phase focused on the installation of high-end equipment and fit-out, customized for the process to manufacture this one-of-a-kind treatment. The fast-track construction schedule included major bid packages for site and foundations, the building shell, interior fit-out and process systems.
